A field guide to BPC-157The criteria
PRODUCT / CARE / COMMITMENT
Open the provider file

Research explained

BPC-157 and drug-induced QTc changes

The work does not establish prevention of dangerous arrhythmias or safe combinations in patients.

On this page

Read the experiment

The finding and its boundary

The authors reported counteraction of QTc prolongation in the rat experiments. The work does not establish prevention of dangerous arrhythmias or safe combinations in patients.

BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.

Experiment
Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
Study system
Rats receiving several neuroleptic or prokinetic challenges
Measured outcome
ECG QTc measurements after acute and repeated exposure
Reported result
The authors reported counteraction of QTc prolongation in the rat experiments.
What this cannot establish
The work does not establish prevention of dangerous arrhythmias or safe combinations in patients.
Open the primary paper

What was actually tested

Rats receiving several neuroleptic or prokinetic challenges. The investigators measured eCG QTc measurements after acute and repeated exposure. The authors reported counteraction of QTc prolongation in the rat experiments.

The detail that changes the takeaway

A QTc measurement is an important electrical marker, but it is not the same endpoint as fewer sudden deaths. Different drugs, baseline conditions and exposures complicate translation. A provider should not use this citation to dismiss interaction screening or established cardiac monitoring.

How far the result travels

The work does not establish prevention of dangerous arrhythmias or safe combinations in patients.

A useful comparison

BPC-157, nitric oxide and anticoagulant-related bleeding examines bleeding, platelet counts and hemostatic measures. Here, the measured endpoint was eCG QTc measurements after acute and repeated exposure. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the Can one BPC-157 study support the product in front of you? appraisal.

References & product documents

The evidence and service information used here.

  1. BPC-157 and drug-induced QTc changes — original indexed research

Next in the field guide

The provider file
  1. 01

    BPC-157, nitric oxide and anticoagulant-related bleeding

    The work does not establish a clinical anticoagulant reversal treatment or safe routine co-use.

  2. 02

    Can one BPC-157 study support the product in front of you?

    Match the claim, ingredient, route and outcome. A relevant paper can still leave the central purchasing question unanswered.

  3. 03

    BPC-157 in gentamicin-related kidney injury

    The experiment does not establish prevention of antibiotic toxicity in patients.

Before you leave

One more option to compare.

Another provider review

We may earn a commission from qualifying provider referrals. Affiliate placements are labeled Partner. How we are funded

Continue to your choiceRead another review